Eikon Therapeutics, Inc. · NASDAQ:EIKN
James B. Tananbaum reported a 7.70% stake in Eikon Therapeutics, Inc. (Schedule 13G)
Event Feb 4, 2026 · Filed Feb 11, 2026
James B. Tananbaum reported a 7.70% stake in Eikon Therapeutics, Inc., 4,148,519 shares, as a passive investor on Feb 4, 2026. Filed Feb 11, 2026 (Schedule 13G).
- Stake
- 7.70%
- Shares
- 4,148,519
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 9 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Foresite Capital Fund IV, L.P. | 3.60% | 1,960,774 |
| Foresite Capital Management IV, LLC | 3.60% | 1,960,774 |
| Foresite Capital Fund V, L.P. | 2.50% | 1,353,168 |
| Foresite Capital Management V, LLC | 2.50% | 1,353,168 |
| Foresite Capital Opportunity Fund V, L.P. | 0.80% | 425,852 |
| Foresite Capital Opportunity Management V, LLC | 0.80% | 425,852 |
| Foresite Capital VI-A, LLC | 0.80% | 408,725 |
| Foresite Capital VI-A Management, LLC | 0.80% | 408,725 |
| James B. Tananbaum | 7.70% | 4,148,519 |
Source
Related
- Eikon Therapeutics, Inc.
- James B. Tananbaum
- Eikon Therapeutics, Inc. shareholders
- Schedule 13G/A · FMR LLC · Oct 7, 2026
- Schedule 13G/A · Abu Dhabi Investment Authority · Oct 2, 2026
- Form 4 · Kutzkey Tim · Sep 8, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13G · Innovation Endeavors III LP · May 15, 2026